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Purpose: The pharmacokinetic properties of mecillinam (MEC) for urinary tract infections are 
excellent, and the resistance rate in Enterobacteriaceae is low compared to other recommended 
antibiotics. The oral prodrug pivmecillinam (P-MEC) has been used successfully as first choice 
for cystitis in the Nordic countries for many years. Norwegian and Danish guidelines also rec-
ommend P-MEC for acute uncomplicated pyelonephritis (AUP) and intravenous (IV) MEC for 
suspected urosepsis (only in Denmark). Here, we wish to present an updated investigation on the 
clinical data behind these recommendations together with sparse but more current clinical data.
Methods: Prospective clinical trials evaluating MEC as monotherapy or in polytherapy with one 
other beta-lactam (mostly ampicillin [AMP]) for pyelonephritis or bacteremia were reviewed. 
Outcomes of primary interest were clinical and bacteriological success and relapse, respectively. 
Search databases used were PubMed, Cochrane Library, and Embase.
Results: Twelve clinical studies (1979–2015) were included in this integrated literature review. 
Clinical success was seen in 38/51 (75%) patients treated with MEC as monotherapy and in 
152/164 (93%) patients treated with MEC and one other beta-lactam. Bacteriological success 
was seen in 35/47 (74%) and 117/167 (70%) patients treated with MEC alone and with one 
other beta-lactam, respectively. In complicated infections, bacteriological success was much 
lower. Clinical relapse rate was not well described. Several uropathogenic bacteremia cases 
were treated successfully with MEC alone (ie, 10/15 [67%] and 13/15 [87%] for clinical and 
bacteriological success, respectively) or with one other beta-lactam (ie, 57/65 [88%] and 53/63 
[84%] for clinical and bacteriological success, respectively). However, data on bacteremia are 
very sparse. Adverse reactions were few and mild (73/406 [18%]) and primarily seen when AMP 
was co-administered (69/73 [95%]). No serious adverse reactions were reported.
Conclusion: IV MEC or oral P-MEC for 14 days may be suitable for the treatment of AUP 
and pediatric pyelonephritis. Randomized controlled trials using a single standardized dose of 
P-MEC compared to other current recommendations are warranted. Similarly, more evidence is 
required before MEC should be recommended for bacteremia or sepsis due to Enterobacteriaceae.
Keywords: pyelonephritis, mecillinam, review, pivmecillinam, amdinocillin
Introduction
Mecillinam (MEC) (known as amdinocillin in the USA) is an antimicrobial drug from 
the amidinopenicillin group that was first introduced in 1972. MEC is selective and 
highly effective against Gram-negative bacteria, especially Escherichia coli.1,2 The oral 
prodrug pivmecillinam (P-MEC) has high bioavailability (~70%), and 45% of the dose 
is secreted in the urine as MEC within 6 hours. Side effects are few and most commonly 
include mild gastrointestinal symptoms.2,3 Community resistance rates are generally 
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low (including in Scandinavia [5%–6%]4–6 where MEC has 
been used for several decades), with a low rate of collateral 
damage and a low risk of clonal spread of resistance.7–12
The international guideline for acute uncomplicated 
pyelonephritis (AUP) recommends that local resistance 
toward an empirical antibiotic should be <10%,13 and as the 
rates of resistance to recommended antibiotics continue to 
rise,8,11 the current recommendations are increasingly lim-
ited.13 The resistance to ciprofloxacin is of particular concern 
because ciprofloxacin is generally the recommended first-line 
therapy for outpatient care of pyelonephritis.13 The present 
pipeline of novel oral antimicrobials is very limited. There-
fore, it is crucial to re-vitalize old antimicrobials for potential 
effectiveness against pyelonephritis. We believe that MEC has 
several interesting properties for this indication, including 
high efficacy for the treatment of lower urinary tract infec-
tions (UTI),3,14–16 high renal tissue concentration compared to 
serum,17 low rates and spread of resistance even in countries 
with high consumption,7–11 and few side effects and synergism 
with other antibiotics.2 MEC also exhibits good in vitro activ-
ity against extended spectrum beta-lactamase (ESBL) and 
carbapenemase producing Enterobacteriaceae;18–22 however, 
clinical utility is still not well established in the literature.23,24
Nevertheless, the potential use of MEC for the treat-
ment of pyelonephritis and urosepsis is not internationally 
acknowledged. The oral prodrug is however recommended 
empirically against AUP in Denmark and Norway (400 mg 
three times daily [tid], for 7–14 days),25–27 or intravenously 
(IV) as MEC (1 g tid) for the treatment of urosepsis,28 but 
the evidence behind these recommendations is not specified 
in the guidelines.
Aim
With this study, we wanted to present an updated investiga-
tion of the clinical trials underlying these recommendations. 
We believe that this could enlighten the medical community 
outside Scandinavia of this old alternative antimicrobial 
drug for especially acute pyelonephritis, where the causative 
bacteria increasingly are resistant to the currently recom-
mended therapies.
Methods
Inclusion criteria
We included prospective clinical trials in children (excluding 
neonates) and adults of MEC/P-MEC as monotherapy or in 
combination with another antibiotic for acute pyelonephritis 
and/or urosepsis/bacteremia. Bacteriological and/or clinical 
effects had to have been evaluated. We did not limit our 
inclusion to randomized controlled trials since there were 
few studies on the subject.
Search strategy
We conducted a widespread search for relevant studies in 
English regardless of age of the studies. We performed an 
unfiltered PubMed search combining the following terms: 
(“pyelonephritis” OR “upper urinary tract infection” OR 
“urinary tract infection” OR “UTI” OR “Sepsis” OR “Septic” 
OR “SIRS” OR “bacteraemia” OR “fever” OR “Febrile”) 
AND (“mecillinam” OR “pivmecillinam” OR “amdinocillin” 
OR “amidinopenicillin”) (N=317). A MeSH database search 
was done with the following mesh words in combination: 
(“Fever” OR “Sepsis” OR “Pyelonephritis” OR “Urinary 
Tract Infections” OR “Systemic Inflammatory Response 
Syndrome” OR “Bacteraemia”) AND (“Amdinocillin” OR 
“Amdinocillin Pivoxil”) (N=169). After removing duplica-
tions, the searches yielded 317 articles. The last search was 
conducted on February 17, 2017. Similar searches in the 
Cochrane Library (N=61) and Embase (N=218) were per-
formed. The reference lists of the included studies and rel-
evant reviews were additionally scanned for relevant clinical 
trials not found in the PubMed and MeSH database search.
Trial selection and data extraction
The primary reviewer selected studies according to inclusion 
criteria and extracted data. Outcomes of interest were clini-
cal success and relapse, as well as bacteriological success 
and relapses. Senior reviewers controlled justifications for 
excluded studies and data extractions. All reviewers evaluated 
the scientific context and relevance of the selected studies 
and data extraction. We extracted data on characteristics such 
as trial design, patients (ie, sex, age, and comorbidities), 
type of infections (ie, pyelonephritis, bacteremia, acute, and 
complicated), pathogens and sensibility, and intervention (ie, 
antibiotics, doses, intervals, and durations). The data were 
analyzed by per-protocol, since majority of the studies used 
this methodology.
Results
Results from the literature search are summarized in  Figure 1. 
We identified 317 articles in the PubMed and MeSH data-
base search, which yielded the included clinical trials.29–38 
The following two clinical trials were further included: one 
from Embase and reference lists39 and one recent quality 
control study on the Danish guidelines by our own research 
group.40 We identified the following 12 prospective clinical 
studies29–40 that met our criteria: two studies on MEC’s effect 
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
9-
M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance  2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
763
Mecillinam for acute pyelonephritis
on uropathogenic bacteremia,30,32 one study on MEC’s effect 
on pediatric pyelonephritis,33 four studies on MEC’s effect 
on pyelonephritis with or without bacteremia,36,38–40 and five 
studies on concomitant MEC and ampicillin (AMP) therapy 
on pyelonephritis with or without bacteremia.31,34,35,37 Three 
studies were prospective noncomparative,32,33,36,40 and eight 
studies were prospective comparative;29–31,34,35,37–39 of these 
studies, six were randomized,29–31,34,38,39 of which only three 
studies were double blinded.29,31,34
Definitions of outcomes
As shown in Table 1, the definitions on treatment effect 
parameters were heterogeneous among the trials. Clinical 
success was defined as relief of symptoms and fever during 
the first 3–7 days.
Bacteriological success was heterogeneously defined; 
it was mainly defined as eradication of bacteria during or 
after therapy, although some studies included “no relapse or 
reinfection” in the definition and some studies defined bacte-
riological relapse separately (range 2–24 weeks). Therefore, 
to make the definition more homogenous in this review, we 
chose a wide definition of bacteriological success: bacterio-
logically cured without relapse or reinfection. This lowered 
the bacteriological success rate in the studies that did not 
include bacteriological relapse or reinfection in the defini-
tion for bacteriological success. Very few studies described 
whether a bacteriological failure, relapse, or reinfection was 
symptomatic.
Outcomes
The 12 included clinical trials are described in Table 1. The 
trials were published from 1979 to 2015. They included a total 
of 296 adult patients with pyelonephritis and/or bacteremia; 
57 patients were treated with P-MEC alone and 239 patients 
were treated with P-MEC and one other beta-lactam. The 
20 pediatric patients with acute pyelonephritis were treated 
with P-MEC alone.
MEC in pyelonephritis
The summarized results for P-MEC for the treatment of 
pyelonephritis are shown in Table 2.38–40 The cumulative 
clinical success and the bacteriological success were 75% and 
Included clinical trials (n=12)
PubMed search (N=317)
Primarily excluded results (n=301)
Articles retrieved for further analyses
(n=16)
Articles excluded after analyses (n=6)
Not on PubMed (n=2)
•    MeSH database search: 169 results
     (all including in the PubMed search) 
•    Not clinical trials
•    More than two antibiotics (n=2)
•    Neonates (n=1)
•    German or Polish (n=2)
•    Embase (n=1)
•    Own data (n=1)
•    LUTI (n=1)
•    Not pyelonephritis or
     uropathogenic bacteremia
Figure 1 Literature search.
Abbreviation: LUTI, lower urinary tract infections.
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
9-
M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
764
Jansåker et al
Table 1 Prospective studies of mecillinam for the treatment of pyelonephritis and Enterobacteriaceae bacteremia
Pyelonephritis
Study Design Intervention Patients 
(N)
Age 
(mean) 
(years)
Temperature 
(°C)
Male: 
female
Bacteremia 
(N)
Complicating 
factors (N)
Estimated 
AUP (N)
Pathogens (S to 
mecillinam) (N)
Clinical 
success
Bacteriological Comment
Success Without relapse/
reinfection
Trollfors 
et al 
(1982)38
Randomized, 
open label, 
comparative
IV: mecillinam 800 mg tid 5 days
Oral: P-MEC 400 mg tid 5 days
Duration: 10 days
25 19–76 (48) ≥38.5 6:19 7 8 ≤17 E. coli (S) (22)
K. pneumoniae (S) (1)
P. mirabilis (S) (2)
15/25 24/25 18/23 (2 lower UTI) The clinical outcome was significantly poorer 
(P<0.05) in patients with mecillinam. The study 
excluded resistant strains and negative culture
IV: cephaloridine 1 g tid 5 days
Oral: cephalexin 500 mg tid 5 days
Duration: 10 days
26 18–83 (55) 6:20 10 10 ≤16 E. coli (S) (24)
K. pneumoniae (S) (2)
P. mirabilis (S) (1)
25/26 26/26 18/24 (3 lower UTI)
Ode et al 
(1983)39
Randomized, 
open label, 
comparative 
IV: mecillinam 1.2 g qid ≥3 days
Oral: P-MEC 400 mg tid
Duration: 28 days
20 19–88 (56) >37.5 4:16 4 6 14 E. coli (S) (17)
E. coli (R) (1)
P. mirabilis (S) (1)
K. pneumoniae (R) (1)
17/20
AUP: 12/14
12/18
AUP: 11/13
The resistant isolates were not evaluable for 
bacteriological evaluation because of change in 
therapy
IV: trimetoprim 160 mg bid ≥3 days
Oral: trimetoprim 160 mg bid
Duration: 28 days
22 32–86 (56) 8:14 5 10 12 E. coli (17)
P. mirabilis (1)
K. pneumoniae (1)
Others (3)
18/22 12/21
IV: AMP 2 g qid ≥3 days
Oral: P-AMP 600 mg tid
Duration: 28 days
21 20–86 (58) 2:19 6 5 15 E. coli (18)
K. pneumoniae (1)
Others (2)
16/21 13/20
Helin 
(1983)33
Open label, 
noncomparative 
(pediatric)
Oral: P-MEC 25–40 mg/kg/day bid or tid
Duration: 10 days
20 0.5–14 (4) >38.5 4:16 – 1 – E. coli (S) (16)
K. pneumoniae (S) (2)
S. saphropyticus (R) (1)
Others (R) (1)
nd 19/20 18/19 Failure was seen in the patient with mixed 
Gram-positive bacteriuria. Relapse was seen 
in the patient with ureteral stenosis (K. 
pneumoniae)
Rotstein 
and 
Farrar 
(1983)37
Open label, 
comparative
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: 4–10 days
11 18–80 (39)a nd ~1/3 male 4 – – E. coli (S) (16)
E. coli (R) (5)
K. pneumoniae (S) (5)
11/11 11/11 nd 3/10 had clinical relapse (intervention group 
nd). In vitro synergism between mecillinam and 
other beta-lactam (P<0.025)IV: mecillinam 10 mg/kg + CCC nd qid
Duration: 4–10 days
9 3 2 – 8/9 9/9
King et al 
(1983)35
Open label, 
comparative 
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: nd
14 nd nd ~50% male nd nd nd Gram-negative bacteria 
(31)
26/28 21/31 Low bacteriological cure rate in subgroup with 
complicated UTI
IV: mecillinam 10 mg/kg + CCC nd qid
Duration: nd
14
Eriksson 
et al 
(1986)31
Randomized, 
open label, 
comparative 
IV: mecillinam 400 mg/AMP 500 mg tid 
(N=15) ~4 days
Oral: P-MEC 200 mg/P-AMP 250 mg tid
Duration: 14 days
27 (IV: 15) 15–86 (55) ≥38 6:21 5 7 20 E. coli (25)
S. saphropyticus (1)
Others (2)
25/27 
(including 
no relapse)
27/27 15/27 (only two 
clinical relapses)
Better clinical outcome in the combination 
group (P=0.002). With only S strains 
(P=0.06). Better bacteriological outcome 
in the combination group (P=0.007). Males 
and complicated infections (P=0.06) and high 
age (P<0.01) were more common in the 
unsuccessful treatment group
IV: AMP 1.4 g or tid ~4 days
Oral: P-AMP 700 mg bid
Duration: 14 days
30 (IV: 17) 16–82 (57) 8:22 9 9 21 E. coli (24)
K. pneumoniae (4)
P. mirabilis (3)
Others (2)
16/30 
(including 
no relapse)
22/30 10/21 (only two 
clinical relapses)
Jernelius 
et al 
(1988)34
Randomized, 
double blinded, 
placebo 
controlled 
Oral: P-MEC /P-AMP 400/500 mg tid 7 days 
+ placebo tid 14 days
Duration: 7 days
32 18–81 (59) ≥38 12:20 5 14 18 E. coli (S) (28)
K. pneumoniae (S) (2)
P. mirabilis (S) (1)
S. saphropyticus (R) (2)
Others (R) (1)
Others (S) (2)
29/32
Relapse: 
3/32
9/32 14/32 Significantly better bacteriological success 
(P=0.004) and lower relapse rate in the 3-week 
group, (P=0.02). Of the nine patients without 
bacteriological success in the 3-week group, 
seven had complicating factors. All bacteria had 
clinical success
Oral: P-MEC /P-AMP 400/500 mg tid 7 days 
+ 200/250 mg tid 14 days
Duration: 21 days
29 16–78 (61) 7:22 4 13 16 E. coli (S) (29)
S. saphropyticus (R) (1)
Others (R) (2)
28/29
Relapse: 
1/29
20/29 23/29
Cronberg 
et al 
(1995)29
Randomized, 
double blinded, 
comparative
IV: mecillinam 600 mg/AMP 1.2 g bid 
~3 days
Oral: P-MEC 400 mg/P-AMP 500 mg bid
Duration: 14 days
65 (61) ≥38.5 Estimated <50% 
male
12 nd nd E. coli (49)
K. pneumoniae (5)
P. mirabilis (2)
Others (12)
41/60 44/60 Therapeutic outcomes, parameters adherence 
rate, and adverse effects were similar in both 
groups. More severe adverse reactions in 
cephalosporin group (ie, diarrhea, Clostridium 
difficile. and fungal superinfection). The study 
used ITT analyses, however, since the majority 
of the studies used PP analysis we decided to 
use that
IV: cefotaxime 2 g bid ~3 days
Oral: cefadroxil 800 mg bid
Duration: 14 days
71 (61) Estimated <50% 
male
20 nd nd E. coli (58)
K. pneumoniae (3)
P. mirabilis (6)
Others (16)
45/70 50/70
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Table 1 Prospective studies of mecillinam for the treatment of pyelonephritis and Enterobacteriaceae bacteremia
Pyelonephritis
Study Design Intervention Patients 
(N)
Age 
(mean) 
(years)
Temperature 
(°C)
Male: 
female
Bacteremia 
(N)
Complicating 
factors (N)
Estimated 
AUP (N)
Pathogens (S to 
mecillinam) (N)
Clinical 
success
Bacteriological Comment
Success Without relapse/
reinfection
Trollfors 
et al 
(1982)38
Randomized, 
open label, 
comparative
IV: mecillinam 800 mg tid 5 days
Oral: P-MEC 400 mg tid 5 days
Duration: 10 days
25 19–76 (48) ≥38.5 6:19 7 8 ≤17 E. coli (S) (22)
K. pneumoniae (S) (1)
P. mirabilis (S) (2)
15/25 24/25 18/23 (2 lower UTI) The clinical outcome was significantly poorer 
(P<0.05) in patients with mecillinam. The study 
excluded resistant strains and negative culture
IV: cephaloridine 1 g tid 5 days
Oral: cephalexin 500 mg tid 5 days
Duration: 10 days
26 18–83 (55) 6:20 10 10 ≤16 E. coli (S) (24)
K. pneumoniae (S) (2)
P. mirabilis (S) (1)
25/26 26/26 18/24 (3 lower UTI)
Ode et al 
(1983)39
Randomized, 
open label, 
comparative 
IV: mecillinam 1.2 g qid ≥3 days
Oral: P-MEC 400 mg tid
Duration: 28 days
20 19–88 (56) >37.5 4:16 4 6 14 E. coli (S) (17)
E. coli (R) (1)
P. mirabilis (S) (1)
K. pneumoniae (R) (1)
17/20
AUP: 12/14
12/18
AUP: 11/13
The resistant isolates were not evaluable for 
bacteriological evaluation because of change in 
therapy
IV: trimetoprim 160 mg bid ≥3 days
Oral: trimetoprim 160 mg bid
Duration: 28 days
22 32–86 (56) 8:14 5 10 12 E. coli (17)
P. mirabilis (1)
K. pneumoniae (1)
Others (3)
18/22 12/21
IV: AMP 2 g qid ≥3 days
Oral: P-AMP 600 mg tid
Duration: 28 days
21 20–86 (58) 2:19 6 5 15 E. coli (18)
K. pneumoniae (1)
Others (2)
16/21 13/20
Helin 
(1983)33
Open label, 
noncomparative 
(pediatric)
Oral: P-MEC 25–40 mg/kg/day bid or tid
Duration: 10 days
20 0.5–14 (4) >38.5 4:16 – 1 – E. coli (S) (16)
K. pneumoniae (S) (2)
S. saphropyticus (R) (1)
Others (R) (1)
nd 19/20 18/19 Failure was seen in the patient with mixed 
Gram-positive bacteriuria. Relapse was seen 
in the patient with ureteral stenosis (K. 
pneumoniae)
Rotstein 
and 
Farrar 
(1983)37
Open label, 
comparative
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: 4–10 days
11 18–80 (39)a nd ~1/3 male 4 – – E. coli (S) (16)
E. coli (R) (5)
K. pneumoniae (S) (5)
11/11 11/11 nd 3/10 had clinical relapse (intervention group 
nd). In vitro synergism between mecillinam and 
other beta-lactam (P<0.025)IV: mecillinam 10 mg/kg + CCC nd qid
Duration: 4–10 days
9 3 2 – 8/9 9/9
King et al 
(1983)35
Open label, 
comparative 
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: nd
14 nd nd ~50% male nd nd nd Gram-negative bacteria 
(31)
26/28 21/31 Low bacteriological cure rate in subgroup with 
complicated UTI
IV: mecillinam 10 mg/kg + CCC nd qid
Duration: nd
14
Eriksson 
et al 
(1986)31
Randomized, 
open label, 
comparative 
IV: mecillinam 400 mg/AMP 500 mg tid 
(N=15) ~4 days
Oral: P-MEC 200 mg/P-AMP 250 mg tid
Duration: 14 days
27 (IV: 15) 15–86 (55) ≥38 6:21 5 7 20 E. coli (25)
S. saphropyticus (1)
Others (2)
25/27 
(including 
no relapse)
27/27 15/27 (only two 
clinical relapses)
Better clinical outcome in the combination 
group (P=0.002). With only S strains 
(P=0.06). Better bacteriological outcome 
in the combination group (P=0.007). Males 
and complicated infections (P=0.06) and high 
age (P<0.01) were more common in the 
unsuccessful treatment group
IV: AMP 1.4 g or tid ~4 days
Oral: P-AMP 700 mg bid
Duration: 14 days
30 (IV: 17) 16–82 (57) 8:22 9 9 21 E. coli (24)
K. pneumoniae (4)
P. mirabilis (3)
Others (2)
16/30 
(including 
no relapse)
22/30 10/21 (only two 
clinical relapses)
Jernelius 
et al 
(1988)34
Randomized, 
double blinded, 
placebo 
controlled 
Oral: P-MEC /P-AMP 400/500 mg tid 7 days 
+ placebo tid 14 days
Duration: 7 days
32 18–81 (59) ≥38 12:20 5 14 18 E. coli (S) (28)
K. pneumoniae (S) (2)
P. mirabilis (S) (1)
S. saphropyticus (R) (2)
Others (R) (1)
Others (S) (2)
29/32
Relapse: 
3/32
9/32 14/32 Significantly better bacteriological success 
(P=0.004) and lower relapse rate in the 3-week 
group, (P=0.02). Of the nine patients without 
bacteriological success in the 3-week group, 
seven had complicating factors. All bacteria had 
clinical success
Oral: P-MEC /P-AMP 400/500 mg tid 7 days 
+ 200/250 mg tid 14 days
Duration: 21 days
29 16–78 (61) 7:22 4 13 16 E. coli (S) (29)
S. saphropyticus (R) (1)
Others (R) (2)
28/29
Relapse: 
1/29
20/29 23/29
Cronberg 
et al 
(1995)29
Randomized, 
double blinded, 
comparative
IV: mecillinam 600 mg/AMP 1.2 g bid 
~3 days
Oral: P-MEC 400 mg/P-AMP 500 mg bid
Duration: 14 days
65 (61) ≥38.5 Estimated <50% 
male
12 nd nd E. coli (49)
K. pneumoniae (5)
P. mirabilis (2)
Others (12)
41/60 44/60 Therapeutic outcomes, parameters adherence 
rate, and adverse effects were similar in both 
groups. More severe adverse reactions in 
cephalosporin group (ie, diarrhea, Clostridium 
difficile. and fungal superinfection). The study 
used ITT analyses, however, since the majority 
of the studies used PP analysis we decided to 
use that
IV: cefotaxime 2 g bid ~3 days
Oral: cefadroxil 800 mg bid
Duration: 14 days
71 (61) Estimated <50% 
male
20 nd nd E. coli (58)
K. pneumoniae (3)
P. mirabilis (6)
Others (16)
45/70 50/70
(Continued)
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Pyelonephritis
Study Design Intervention Patients 
(N)
Age 
(mean) 
(years)
Temperature 
(°C)
Male: 
female
Bacteremia 
(N)
Complicating 
factors (N)
Estimated 
AUP (N)
Pathogens (S to 
mecillinam) (N)
Clinical 
success
Bacteriological Comment
Success Without relapse/
reinfection
Nicolle 
and 
Mulvey 
(2007)36
Case report Oral: P-MEC 400 mg bid
Duration: 2 years
1 47 nd 0:1 – 1 0 ESBL – E. coli (S) (1) Bacteriological and clinical success was seen 
over the following weeks after initiating the 
therapy, no relapse of ESBL producing E. coli 
over following 2 years
Jansåker 
et al 
(2015)40
Observational 
noncomparative
Oral: P-MEC 400 mg tid
Duration: 14 days
6 23–78 (47) nd 0:6 – 0 6 E. coli (S) (6)
K. pneumoniae (S) (1)
6/6 6/6 4/5 (relapse: 
asymptomatic)
Including retrospective cases: bacteriological 
and clinical success 17/22 (77%). Bacteriological 
relapse 7/22 (32%). One ESBL producing E. coli 
infection with treatment success
Enterobacteriaceae bacteremia
Study Design Intervention Number of 
patients
Age (median) 
(years)
Male:female Complicating 
factors
Pathogens Results and comments
Frimodt-
Møller 
and Ravn 
(1979)32
Observational 
noncomparative
IV: mecillinam 10 mg/kg qid with/without 
one other antibiotics
Duration: 4–10 days (median 7)
5 47–85 (78) 1:4 All patients had serious 
comorbidities and 
impaired renal function
E. coli (S) (2)
K. pneumoniae (S) (2)
K. oxytoca (S) (1)
2/2 with monotherapy had clinical and bacteriological success
3/3 with concomitant therapy had clinical and bacteriological success
Ekwall 
et al 
(1980)30
Randomized, 
open label, 
comparative
IV: mecillinam 10 mg/kg qid 7–14 days
Oral: P-MEC 400 mg tid
Duration: 21 days
3 56–86 (57) 1:2 nd E. coli (S)
Citrobacter sp (S)
K. pneumoniae (S)
2/3 had clinical and bacteriological success
1/3 had clinical and bacteriological failure (female with K. pneumoniae)
IV: mecillinam 5 mg/kg + AMP 15 mg/kg qid 
7–14 days
Oral: P-MEC 200 mg + P-AMP 350 mg tid
Duration: 21 days
5 21–73 (45) 3:2 nd E. coli (S) (4)
K. pneumoniae (S)
4/5 had clinical and bacteriological success
1/5 had clinical and bacteriological failure (male with E. coli)
Nonrandomized IV: mecillinam 10 mg/kg + AMP 30 mg/kg qid 
7–14 days
Oral: P-MEC 400 mg + P-AMP 700 mg tid
Duration: 21 days
5 52–87 (65) 3:2 Patients with serious 
comorbidities
E. coli (S) (3)
Citrobacter sp (S)
P. mirabilis (S) (2)
4/5 had clinical and bacteriological success
1/5 had clinical and bacteriological failure (male with Ec and Citrobacter sp)
King et al 
(1983)35
Open-label 
comparative 
(stratified cases)
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: nd
11 b ~50% male b Gram-negative bacteria 11/11 had clinical and bacteriological success 
IV: mecillinam 10 mg/kg + CCC nd qid
Duration: nd
14 13/14 had clinical and bacteriological success 
Notes: aIncluding five cases with other infections. bStratified cases of bacteremia caused by pyelonephritis (for detailed data refer Table 2).
Abbreviations: AMP, ampicillin; AUP, acute uncomplicated pyelonephritis; bid, two times daily; CCC, cephalosporin or carbenicillin; E. coli, Escherichia coli; ESBL, extended 
spectrum beta-lactamase; GI, gastrointestinal; ITT, intention to treat; IV, intravenous; K. oxytoca, Klebsiella oxytoca; K. pneumoniae, Klebsiella pneumoniae; nd, no data/not 
described; P. mirabilis, Proteus mirabilis; P-AMP, pivampicillin; P-MEC, pivmecillinam; PP, per protocol; qid, four times daily; SAR, severe adverse reaction; S, sensitive; 
S. saphropyticus, Staphylococcus saphropyticus; tid, three times daily; UTI, urinary tract infections.
Table 1 (Continued)
74%, respectively. Considerably higher treatment failure was 
found in complicated infections (ie, high age, males, bacte-
remia, and females with predisposing factors),38,39 and high 
treatment success was seen in the studies where AUP could 
be stratified.38,40 There are two cases with treatment success 
with P-MEC in pyelonephritis caused by ESBL producing 
E. coli.36,40 In a comparative study, MEC (800 mg tid) had 
significantly lower clinical success than cephaloridine 1 g tid 
(P<0.05).38 With a higher initial MEC dose of 1200 mg four 
times daily (qid), an overall superior treatment success was 
achieved compared to MEC 800 mg tid and with no differ-
ence compared to AMP and trimethoprim.39
To our knowledge, there is only one pediatric clinical 
study on P-MEC.33 The author found an excellent bacterio-
logical success (19/20) of P-MEC in children (0.5–14 years) 
with pyelonephritis, when administered as 25–40 mg/kg/day 
two times daily (bid)/tid for 10 days.
The summarized results for P-MEC combined with 
another beta-lactam (pivampicillin [P-AMP] in 141/163) 
for pyelonephritis are listed in Table 2. The clinical success 
and the bacteriological success were 93% and 70%, respec-
tively. The combination of P-AMP/P-MEC had excellent 
clinical success within the first week of treatment. How-
ever, Jernelius et al found that the bacteriological success 
was 39% and 88% for AUP, with 1- and 3-week therapies, 
respectively (P=0.02). Symptomatic relapses were mainly 
lower UTI in both groups, and the few relapses found in the 
3-week therapy were asymptomatic in >80% of the cases.34 
The 2-week therapy demonstrated intermediate results as 
compared to the 1- and 3-week therapies.29,31 One study used 
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Pyelonephritis
Study Design Intervention Patients 
(N)
Age 
(mean) 
(years)
Temperature 
(°C)
Male: 
female
Bacteremia 
(N)
Complicating 
factors (N)
Estimated 
AUP (N)
Pathogens (S to 
mecillinam) (N)
Clinical 
success
Bacteriological Comment
Success Without relapse/
reinfection
Nicolle 
and 
Mulvey 
(2007)36
Case report Oral: P-MEC 400 mg bid
Duration: 2 years
1 47 nd 0:1 – 1 0 ESBL – E. coli (S) (1) Bacteriological and clinical success was seen 
over the following weeks after initiating the 
therapy, no relapse of ESBL producing E. coli 
over following 2 years
Jansåker 
et al 
(2015)40
Observational 
noncomparative
Oral: P-MEC 400 mg tid
Duration: 14 days
6 23–78 (47) nd 0:6 – 0 6 E. coli (S) (6)
K. pneumoniae (S) (1)
6/6 6/6 4/5 (relapse: 
asymptomatic)
Including retrospective cases: bacteriological 
and clinical success 17/22 (77%). Bacteriological 
relapse 7/22 (32%). One ESBL producing E. coli 
infection with treatment success
Enterobacteriaceae bacteremia
Study Design Intervention Number of 
patients
Age (median) 
(years)
Male:female Complicating 
factors
Pathogens Results and comments
Frimodt-
Møller 
and Ravn 
(1979)32
Observational 
noncomparative
IV: mecillinam 10 mg/kg qid with/without 
one other antibiotics
Duration: 4–10 days (median 7)
5 47–85 (78) 1:4 All patients had serious 
comorbidities and 
impaired renal function
E. coli (S) (2)
K. pneumoniae (S) (2)
K. oxytoca (S) (1)
2/2 with monotherapy had clinical and bacteriological success
3/3 with concomitant therapy had clinical and bacteriological success
Ekwall 
et al 
(1980)30
Randomized, 
open label, 
comparative
IV: mecillinam 10 mg/kg qid 7–14 days
Oral: P-MEC 400 mg tid
Duration: 21 days
3 56–86 (57) 1:2 nd E. coli (S)
Citrobacter sp (S)
K. pneumoniae (S)
2/3 had clinical and bacteriological success
1/3 had clinical and bacteriological failure (female with K. pneumoniae)
IV: mecillinam 5 mg/kg + AMP 15 mg/kg qid 
7–14 days
Oral: P-MEC 200 mg + P-AMP 350 mg tid
Duration: 21 days
5 21–73 (45) 3:2 nd E. coli (S) (4)
K. pneumoniae (S)
4/5 had clinical and bacteriological success
1/5 had clinical and bacteriological failure (male with E. coli)
Nonrandomized IV: mecillinam 10 mg/kg + AMP 30 mg/kg qid 
7–14 days
Oral: P-MEC 400 mg + P-AMP 700 mg tid
Duration: 21 days
5 52–87 (65) 3:2 Patients with serious 
comorbidities
E. coli (S) (3)
Citrobacter sp (S)
P. mirabilis (S) (2)
4/5 had clinical and bacteriological success
1/5 had clinical and bacteriological failure (male with Ec and Citrobacter sp)
King et al 
(1983)35
Open-label 
comparative 
(stratified cases)
IV: mecillinam 10 mg/kg + AMP nd qid
Duration: nd
11 b ~50% male b Gram-negative bacteria 11/11 had clinical and bacteriological success 
IV: mecillinam 10 mg/kg + CCC nd qid
Duration: nd
14 13/14 had clinical and bacteriological success 
Notes: aIncluding five cases with other infections. bStratified cases of bacteremia caused by pyelonephritis (for detailed data refer Table 2).
Abbreviations: AMP, ampicillin; AUP, acute uncomplicated pyelonephritis; bid, two times daily; CCC, cephalosporin or carbenicillin; E. coli, Escherichia coli; ESBL, extended 
spectrum beta-lactamase; GI, gastrointestinal; ITT, intention to treat; IV, intravenous; K. oxytoca, Klebsiella oxytoca; K. pneumoniae, Klebsiella pneumoniae; nd, no data/not 
described; P. mirabilis, Proteus mirabilis; P-AMP, pivampicillin; P-MEC, pivmecillinam; PP, per protocol; qid, four times daily; SAR, severe adverse reaction; S, sensitive; 
S. saphropyticus, Staphylococcus saphropyticus; tid, three times daily; UTI, urinary tract infections.
a lower dose of P-MEC/P-AMP (0.2/0.25 g tid)31 compared 
to similar trials.29,34 The bacteriological success (56%) and 
overall success (ie, both clinical success and bacteriological 
success without relapse) in AUP (55%) were much lower in 
this study31 compared to the other studies, where the bacterio-
logical success was ~69%29,34 and the overall success in AUP 
was 81%.34 In the two studies that cases could be stratified 
into uncomplicated or complicated pyelonephritis, the overall 
success rates were 67% and 25%, respectively. It was found 
that patients of high age, males, and females with predispos-
ing factors demonstrated a considerably lower and insufficient 
treatment success, mostly because of bacteriological fail-
ure.31,34 Eriksson et al31 found that MEC combined with AMP 
was superior both clinically and bacteriologically to AMP 
alone, in spite of a lower dosage in the combination therapy. 
AMP monotherapy was associated with higher selection of 
resistant strains to both AMP (P=0.02) and MEC (P=0.06) 
compared to combination therapy, which was not associated 
with the selection of resistant strains. Cronberg et al29 found 
that MEC combined with AMP for 14 days (IV followed by 
oral administration) had similar rates for treatment success, 
treatment discontinuation, and bacteriological relapses for 
acute pyelonephritis as treatment with a cephalosporin (IV 
followed by an oral administration). The relapse rate was 
similar to other studies on the MEC/AMP combination.30,34,39 
Two studies compared MEC (10 mg/kg qid) combined with 
either AMP or cephalosporines (doses not defined).45,46 One 
of these studies found that both combinations had equal 
excellent outcome after a 4- to 10-day therapy.37 The second 
study found that the AMP combination had an inferior bac-
teriological success (duration not defined); yet, there was no 
difference in the bacteremia group.35
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MEC in bacteremia
The data are very sparse on MEC given as monotherapy for 
bacteremia caused by Enterobacteriaceae. The results from 
the studies we found are listed in Table 3. Cumulatively, the 
clinical success and the bacteriological success were 67% 
(10/15) and 87% (13/15), respectively. The results for MEC 
combined with another beta-lactam (mostly AMP) on bac-
teremia caused by Enterobacteriaceae are listed in Table 3. 
Cumulatively, the clinical success and the bacteriological 
success were 88% (57/65) and 84% (53/63).
Adverse reactions
The cumulative results of adverse reactions with MEC with/
without AMP for pyelonephritis and/or uropathogenic bac-
teremia are shown in Table 4. There was no serious adverse 
reaction, but approximately one of the five patients had an 
adverse reaction, which was mainly seen in the concomitant 
therapy groups.
Discussion
MEC has been used for AUP for several years in parts of 
Scandinavia. We found no evidence that MEC should be 
an insufficient alternative against AUP, but insufficient 
for patients with acute complicated pyelonephritis on 
bacteriological outcome, even when combined with AMP. 
Table 2 Effect of mecillinam and mecillinam in combination with other beta-lactams for the treatment of pyelonephritis with and 
without bacteremia
Mecillinam 
Reference Without predisposing factors (AUP) With predisposing factors All pyelonephritis 
Clinical 
success
Bacteriological success 
(without relapse/
reinfections)
Clinical 
success
Bacteriological success 
(without relapse/
reinfections)
Clinical 
success
Bacteriological 
success (without 
relapse/reinfections)
Ode et al39 12/14 11/13a 5/6 1/5b 17/20 12/18a,b
Trollfors et al38 Not possible to determine 15/25 18/23c
Jansåker et al40 6/6 5/6 – – 6/6 5/6
Total 18/20 (90%) 16/19 (84%) 5/6 (83%) 1/5 (20%) 38/51 (75%) 35/47 (74%)
Mecillinam in combination with other beta-lactams
Reference Without predisposing factors (AUP) 
(overall successd)
With predisposing factors (overall 
successd)
All acute pyelonephritis
Clinical 
success
Bacteriological 
success (without 
relapse/reinfections)
Rotstein and 
Farrar37
Not possible to determine Not possible to determine 16/20 20/20
King et al35 Not possible to determine Not possible to determine 26/28 21/31
Eriksson et al31 11/20 4/7 25/27 15/27
Jernelius et al34,e 13/16 1/13 28/29 20/29
Cronberg et al29 Not possible to determine Not possible to determine 57/60 41/60 
Total 24/36 (67%) 5/20 (25%) 152/164 (93%) 117/167 (70%)
Notes: aResistant E. coli was not evaluable because change in therapy. bResistant K. pneumoniae was not evaluable because change in therapy. cTwo dropouts, three 
asymptomatic bacteriuria (different strains), and two bacteriuria with symptoms of LUTI. dDefined as both clinical success and bacteriological success, without bacteriological 
relapse. eSince it was significantly inferior, the 1-week therapy was not included.
Abbreviations: AUP, acute uncomplicated pyelonephritis; K. pneumoniae, Klebsiella pneumoniae; E. coli, Escherichia coli.
Table 3 Effect of mecillinam and mecillinam in combination with 
other beta-lactams for the treatment of bacteremia caused by 
Enterobacteriaceae
Reference Cases Clinical 
success
Bacteriological 
success (without 
relapse/
reinfections)
Mecillinam
Frimodt-Møller and Ravn32 2 2/2 2/2
Ekwall et al30 3 2/3 2/3
Ode et al39 3 3/3 3/3
Trollfors et al38 7 3/7 6/7
Total 15 10/15 (67%) 13/15 (87%)
Mecillinam in combination with other beta-lactams
Frimodt-Møller and Ravn32 3 3/3 3/3
Ekwall et al30,a 10 8/10 8/10
Rotstein and Farrar37 7 7/7 7/7
King et al35 25 24/25 24/25
Eriksson et al31 4 4/4 2/2
Jernelius et al34,b 4 4/4 2–3/4
Cronberg et al29 12 7/12 7/12
Total 64 57/65 (88%) 53/63 (84%)
Notes: aTwofold doses in 50% of the patients. bSince the 1-week therapy was 
significantly inferior, it is not included in this table.
From the published results, it seems that the regimen for 
AUP in adults should be P-MEC ≥400 mg tid (adjusted for 
weight) for at least 14 days in adults with/without initially 
IV MEC. Both clinical33 and retrospective data on resistance 
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rates41 support a recommendation of P-MEC in pediatric 
pyelonephritis, administered as 25–40 mg/kg/day bid/tid 
for 10 days.33
The low bacteriological success rates in pyelonephritis31 
and lower UTI caused by ESBL producing bacteria24 can 
largely be explained by suboptimal dosing with P-MEC 
200 mg tid. Higher dosage and shorter dosing interval of 
MEC for UTI are suggested to attain sufficient time above 
minimal inhibitory concentration (MIC),42 especially for 
ESBL producing E. coli (manuscript in preparation). Studies 
similar to Eriksson et al31 that administered P-MEC as 400 mg 
instead of 200 mg demonstrated a higher bacteriological 
success rate.29,34 Similarly, the lesser clinical effect of MEC 
compared to cephaloridine for pyelonephritis38 could also be 
explained by the lower dosage of 800 mg tid, since no dif-
ference was found when dosing MEC 1.2 g qid compared to 
AMP and trimethoprim.39 Hence, a higher dose of P-MEC, 
eg, 1000 mg tid, could be more beneficial in pyelonephritis 
than the currently recommended doses, which should also be 
sufficient for ESBL producing strains. The duration should 
be 14 days in pyelonephritis as the bacteriological effect 
seems to increase with duration,29,31,34 and since there is still 
missing solid evidence that a short (eg, 7 days) course is 
sufficient for P-MEC.
Interestingly, MEC with or without AMP demonstrated 
satisfactory success on bacteremia caused by Enterobacte-
riaceae.29–32,34,35,37–39 A Danish retrospective study reported a 
favorable 30-day mortality outcome of MEC (23%) com-
pared to other antibiotics (43%) for Klebsiella pneumoniae 
bacteremia (OR 0.4, 95% CI 0.2–0.9).43 Although MEC 
seems to be effective against selected cases of uropathogenic 
bacteremia, we do not recommend MEC to be used alone 
when urosepsis is suspected but administered together with 
an aminoglycoside to broaden the antimicrobial spectra for 
empirical treatments.
Synergism with MEC and other beta-lactams occurs 
because MEC is an amidinopenicillin, with more selective 
affinity to penicillin-binding protein 2, as compared with 
aminopenicillins or cephalosporines.44 This synergism has 
been investigated clinically in a few studies,29–31,34,37 but only 
one study found a significant difference (P<0.025).37 Cumu-
latively, there seems to be a difference in outcomes between 
monotherapy and combination therapy (75% and 93% clini-
cal success, respectively), which could be explained by the 
synergistic effect. MEC alone was also seen bacteriologically 
inferior in pyelonephritis compared to a cephalosporin,38 
but not when combined with AMP.29 Synergism and higher 
bactericidal activity have also been demonstrated in vitro 
between MEC and clavulanic acid.18,45
The side effects of monotherapy with P-MEC are 
described as few and mild.2 This is similar to the findings of 
this study (Table 4). However, concomitant therapy of MEC 
and AMP was associated with mild adverse reactions in one 
of the five patients treated.
A major limitation with these old studies is that they fail 
to describe the clinical details in the cases of bacteriological 
failures/relapses, which was frequently seen in many papers 
regarding complicated infections. This is of major importance 
since asymptomatic bacteriuria is much less worrisome than a 
symptomatic bacteriological failure/relapse. Thus, we believe 
that clinical success represents the major outcome, which was 
excellent in the majority of the studies.
Although the reviewed studies were well designed and 
conducted at the time, they were conducted several decades 
Table 4 ARs of mecillinam as monotherapy or combined with AMP
Reference Therapy Exanthema GI Others Total AR Total SAR
Frimodt-Møller and Ravn32 MEC or MEC/AMP 0 0 0 0/5 0/5
Ekwall et al30,a MEC/AMP, P-MEC/P-AMP 4 0 0 5/73 0/73
Ekwall et al30 MEC/P-MEC 1 0 0
Ode et al39 MEC/P-MEC 1 2 0 3/20 0/20
Trollfors et al38 MEC/P-MEC 0 0 0 0/25 0/25
Helin33 (pediatric) P-MEC 0 0 0 0/19 0/19
Eriksson et al31 MEC/AMP 7 4 5 16/43 0/43
Jernelius et al34 P-MEC/P-AMP 1 2 2 5/38 0/38
Jernelius et al34 (21 days) P-MEC/P-AMP 0 11 1 12/39 0/39
Cronberg et al29 MEC/AMP, P-MEC/P-AMP 12 15 5 32/144 0/144
Total Cumulative 26 34 13 73/406b (18%) 0/406 (0%)
Total MEC 2 2 0 4 0
Total MEC/AMP 24 32 13 69 0
Notes: We did not include the studies that did not report, specify, and/or categorize the side effects. aHalf had double dose. bSome patients had more than one AR.
Abbreviations: AMP, ampicillin; AR, adverse reaction; GI, gastrointestinal; MEC, mecillinam; P-AMP, pivampicillin; P-MEC, pivmecillinam; SAR, serious adverse reaction.
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ago, comparator drugs are uncommon today, the included 
sample sizes were generally small, the clinical picture on 
bacteriological failure/relapse was limited, and many used 
definitions of disease and outcome that vary from current 
standards. This severely limits the possibility to provide 
sufficient evidence-based recommendations to treat AUP 
with MEC. Therefore, there is an urgent need of clinical 
controlled trials comparing a single, standardized dose 
of P-MEC/MEC with other currently recommended anti-
microbial treatments of uncomplicated and complicated 
pyelonephritis and sepsis.
A recent meta-analysis on the duration of antibiotic 
therapy for pyelonephritis with or without bacteremia con-
cluded that 7 days of treatment is equivalent to longer thera-
pies (including beta-lactams).46 However, the analysis only 
included one study with MEC,34 in which 7 days was found 
to be significantly bacteriologically inferior to 21 days of 
treatment. With this in consideration, we believe that the first 
randomized control study on the subject preferably should 
be a noninferiority trail comparing MEC in a higher dosage 
of 1000 mg tid with ciprofloxacin in currently recommended 
dosage13 for 7 days.
Conclusion
MEC is an important older antimicrobial drug, which based 
on limited number of studies may be considered as an alter-
native in AUP, especially in patients with high predicted 
probability of bacteria with resistance to fluoroquinolone 
and other first-line agents. MEC may also be considered for 
pediatric pyelonephritis. Randomized clinical trial comparing 
the drug with standard of care regimens is warranted. There 
are currently no sufficient data to support the use of MEC in 
patients with bacteremia or sepsis due to Enterobacteriaceae.
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